Binary Pharmaceuticals, LLC


Burke Pharmaceutical Research is a clinical trial facility located in Hot Springs, Arkansas, specializing in dermatology research. With over 20 years of experience, they conduct Phase I through Phase III trials, focusing on dermatologic conditions. Their mission is to provide high-quality clinical trial services in a professional environment, ensuring participant understanding and safety. They have a dedicated staff, modern facilities, and a strong network of referring physicians.

Industries

assistive-technology
clinical-trials
health-care

Nr. of Employees

small (1-50)

Binary Pharmaceuticals, LLC


Services

Full-service site operations for dermatology clinical trials including screening, enrollment, study visits, and protocol adherence.

Patient identification, screening, and retention services supported by an internal patient database and referral networks.

On-site infusion room for intravenous investigational therapies and space for conducting physical exams and ECGs.

Standardized dermatology imaging using professional camera equipment and multiple lighting modalities for objective endpoint documentation.

Secure, access-controlled drug storage with pharmaceutical-grade refrigeration/freezer units and emergency power backup.

Ongoing availability of research personnel for participant questions and coordination, and management of travel reimbursement for qualifying participants.

Expertise Areas

  • Clinical trial management
  • Dermatology clinical research
  • Patient recruitment and retention
  • On-site clinical photography and imaging
  • Show More (3)

Key Technologies

  • Phase I–III clinical trial operations
  • Randomized double-blind and placebo/vehicle-controlled study designs
  • Medical photography (DSLR, reflected UV, macro, stereotactic)
  • Outpatient infusion therapy
  • Show More (4)

News & Updates

A year-long clinical research study to evaluate the safety and efficacy of an investigational drug for HS, involving participants aged 16 and older diagnosed with HS for at least 6 months.

A global, year-long clinical research study investigating the safety and effectiveness of an investigational drug, Barzolvolimab, for CSU. Participants must be 18 or older, diagnosed with CSU for at least 6 months, and experiencing symptoms despite treatment.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.